$藥明康德.HK公告,預計 2022 年淨利潤 88.14 億元,同比增長約 72.91%。公司獨特的 CRDMO(合同研究、開發與生產)和 CTDMO(合同測試、研發與生產)業務模式持續驅動公司高速發展。

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Like